Which one of the following drugs does not undergo the hepatic first-pass effect:
**Core Concept**
The hepatic first-pass effect refers to the significant metabolism of a drug by the liver during its first pass through the hepatic circulation after oral administration, resulting in a substantial reduction of the drug's bioavailability. This phenomenon is particularly relevant for lipophilic and basic drugs.
**Why the Correct Answer is Right**
The correct answer is **D. Furosemide**. Furosemide is a loop diuretic that is primarily excreted unchanged in the urine without undergoing extensive hepatic metabolism. As a result, its bioavailability is relatively high, and it does not undergo significant first-pass metabolism. The liver does not play a significant role in the metabolism of furosemide, making it an exception to the first-pass effect.
**Why Each Wrong Option is Incorrect**
* **Option A:** **Warfarin** is an anticoagulant that undergoes significant hepatic metabolism, including oxidation and conjugation reactions. The liver plays a crucial role in the metabolism of warfarin, making it subject to the first-pass effect.
* **Option B:** **Nifedipine** is a calcium channel blocker that is extensively metabolized by the liver, particularly by the cytochrome P450 enzyme system. This extensive hepatic metabolism contributes to the first-pass effect and reduces its bioavailability.
* **Option C:** **Lidocaine** is a local anesthetic that undergoes significant hepatic metabolism, including oxidation and conjugation reactions. The liver plays a crucial role in the metabolism of lidocaine, making it subject to the first-pass effect.
**Clinical Pearl / High-Yield Fact**
When considering the first-pass effect, it is essential to remember that lipophilic and basic drugs are more susceptible to hepatic metabolism and reduced bioavailability. This knowledge can help clinicians predict and manage the pharmacokinetics of various medications.
**Correct Answer: D. Furosemide**